

FORM PTO-1449 (REV. 7-30-03)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866									
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use separate sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003									
				GROUP: 1615											
U.S. PATENT DOCUMENTS															
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
JLS	AA	3	4	4	4	2	4	6	06/22/1976	Leslie	424	22			
	AB	4	2	4	4	4	4	6	12/02/1980	Dudzinski	424	260			
	AC	4	3	4	4	3	4	0	12/28/1992	Leslie	536	56			
	AD	4	4	4	9	4	4	8	04/17/1984	Oshlack, et al.	424	22			
	AE	9	4	4	9	4	9	5	05/09/1989	Elger, et al.	424	419			
	AF	4	6	6	4	6	6	5	05/30/1989	Martani, et al.	424	488			
	AG	4	4	9	4	9	9	8	05/30/1989	Goldie, et al.	424	485			
	AH	4	4	4	4	4	4	5	05/30/1989	Elger, et al.	424	488			
	AI	4	4	4	4	9	4	4	07/04/1989	Elger, et al.	424	485			
	AJ	4	4	4	4	4	4	9	07/04/1989	Goldie, et al.	424	419			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
JLS	AK	0	1	9	3	3	5	5	09/03/1986	Europe (A3)	A61K	31/615			
	AJ	4	3	7	9	4	4	3	06/07/1989	Europe (A1)	A61K	31/485			
	AM	0	4	4	9	4	4	9	11/07/1990	Europe (A2)	A61K	31/485			
	AA	4	4	4	4	9	4	7	01/13/2000	WO	A61K	31/00			
	AG	9	0	0	4	9	9	9	05/17/1990	WO	A61K	31/485			
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)															
JLS	AP	Translation of previously submitted German patent application DE 43 25 465 1995													
JLS	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53: pg. 1201-1205													
JLS	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52: pg. 659-663													
EXAMINER <i>Chunhua Y. Ma</i>										DATE CONSIDERED 7/23/07					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 101689,856							
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.							
						FILING DATE: October 21, 2003		GROUP: 1615					
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
JS	BN	4	9	9	4	9	4	0	07/04/1989	Leslie, et al.	424	494	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
										YES	NO		
	BN												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
JS	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9											
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429.											
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83											
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 <sup>th</sup> National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349											
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
	BB	Briscoe, et al., "Methocloctonnamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399											
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Moth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551											
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343											
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol-and Thera (1974) Vol. 15: No. 6 pg. 556-564											
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F 1973											
	BN	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May; 51 (5) pg. 713-737											
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8											
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Thera (1984) Vol. 36, No. 5, pg. 704-708											
	BP	Cormier, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159, pg. 351-360											
JS	BQ	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280											
EXAMINER		Jumana V. Oshlack						DATE CONSIDERED					
								07/23/07					


\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/889,566		
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshack, et al.				
				FILING DATE: October 21, 2003		GROUP: 1615		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>js</i>	DA	4	0	0	0	5	5	7
					07/10/1990	Jenkins, et al.	424	480
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
								YES NO
	DA							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>js</i>	DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39						
	DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arznieim-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744						
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135						
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176						
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257						
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846						
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174						
	DJ	Slevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211						
	DI	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458						
	DC	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209						
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242						
	DH	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993						
	DO	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383						
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634						
	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages						
<i>js</i>	DR	Umbrecht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190						
EXAMINER <i>Shirley A. Smith</i>					DATE CONSIDERED <i>7/23/07</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/589,866							
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003							
				GROUP: 1615									
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
0/8	EA	0	0	7	0	0	7	5	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
									YES	NO			
	EB												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
0/8	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034											
	ED	Wang, et al., "Inverse agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600											
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261 1976											
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342											
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoR1 9409, a Nonpeptidic Opioid $\mu$ -Agonists/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605											
	EH	Wodak, Alex., "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6											
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148											
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336											
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine produg controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209											
	EL	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445											
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94											
	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630											
0/8	EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385											
EXAMINER <i>Shunee 2/2008</i>						DATE CONSIDERED 07/23/07							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,666	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
J/S	FB 8 8 8 8 3 3 6	01/22/1991	Kreek, et al.	514	282		
	FB 4 4 4 4 3 3 3	02/05/1991	Goldie, et al.	424	468		
	FC 0 0 2 1 0 0 0	12/10/1991	Matkowska, et al.	424	468		
	FD 0 0 2 8 8 8 8	02/25/1992	Heafield, et al.	424	457		
J/S	FB 5 2 0 8 8 0 8	08/01/1993	Krishnamurthy	424	468		
	FC 0 2 2 0 3 3 1	07/13/1993	Thompson, et al.	73	885.9		
	FC 0 2 0 0 3 3 1	11/30/1993	Oshlack, et al.	424	468		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	FH						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
J/S	FI	Budd, Keith, "Clinical use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011					
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; Proc. Natl. Acad. Sci (1995) Vol 92, pp. 10540-10544					
	FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105					
	FL	Leeling, et al., "Disposition and metabolism of codeorphine in the rat, dog and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp. 649-653					
	FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152					
	FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130					
	FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pp. 420-426					
	FR	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pp. 29-37					
	FQ	Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pp. 355-363					
	J/S	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pp. 906-909				
EXAMINER <i>Shirley J. Oshlack</i>			DATE CONSIDERED 7/23/07				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/889,886								
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.								
						FILING DATE: October 21, 2003		GROUP: 1615						
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JS	GA	5	2	3	2	4	6	3	02/15/1994	Oshlack, et al.	424	488		
	Gi	5	3	2	1	3	8	8	06/28/1994	Oshlack, et al.	106	153		
	GG	6	6	6	6	6	6	6	08/09/1994	Raffa, et al.	514	629		
	GE	5	3	6	6	4	6	6	10/16/1994	Oshlack, et al.	106	153		
	GE	5	1	1	1	7	8	6	05/02/1995	Oshlack, et al.	424	456		
JS	GI	5	1	6	6	3	8	6	10/24/1995	Merrill, et al.	424	470		
	GG	5	6	6	6	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
JS	GH	5	1	6	1	2	8	2	03/12/1987	WO	A61K	31/485		
	GI	6	6	6	6	1	1	6	05/10/2001	WO (A2)	A61K	31/485		
	GJ	6	1	6	6	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
JS	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1, pg. 29-34												
	GI	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151												
	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
	GI	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
JS	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577												
EXAMINER										DATE CONSIDERED				
										7/23/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866									
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		GROUP: 1615									
				FILING DATE: October 21, 2003											
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
J/S	HA	5	0	0	0	5	7	7	12/26/1995	Sackler, et al.	424	468			
	HA	5	5	0	0	7	7	7	03/19/1996	Oshlack, et al.	424	494			
	HG	5	0	0	0	0	0	2	04/16/1996	Oshlack, et al.	424	468			
	HD	5	5	0	0	0	4	3	04/16/1996	Krishnamurthy	424	484			
	HE	5	5	4	0	0	1	2	08/27/1996	Oshlack, et al.	424	468			
	HE	5	5	5	7	5	7	2	09/03/1996	Gauthier, et al.	514	468			
	HG	5	5	0	7	7	5	7	01/07/1997	Miller, et al.	424	468			
	HH	5	0	7	7	5	0	5	02/11/1997	Buxton, et al.	424	468			
	HJ	5	0	7	2	0	7	7	04/22/1997	Knott, et al.	424	494			
	HJ	5	0	0	0	0	2	6	06/17/1997	Oshlack, et al.	424	468			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
	HK														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
J/S	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160													
	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607													
	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylmorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442													
	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46													
	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101													
	HQ	Nuti, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166 1973													
J/S	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948 1973													
EXAMINER										DATE CONSIDERED					
J/S										1/23/07					
*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
g/s	IA	5	8	8	5	5	5	5	08/12/1997	Oshlack, et al.	424	494	
	IB	8	6	1	0	1	7	2	09/23/1997	Buxton, et al.	424	495	
	IB	5	5	1	1	1	5	5	09/30/1997	Sackler, et al.	424	495	
	ID	5	6	8	5	5	5	5	10/28/1997	Oshlack, et al.	424	494	
	IB	5	7	6	8	4	5	7	06/09/1998	Miller, et al.	424	282	
	IB	5	8	8	5	1	7	5	07/14/1998	Kim	514	282	
	IG	5	8	1	1	1	7	8	09/22/1998	Krishnamurthy	424	495	
g/s	IB	8	8	3	3	8	7	7	11/10/1998	Mioduszewski	514	282	
	II	5	5	8	8	8	8	0	12/01/1998	Miller, et al.	424	495	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	U												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
g/s	IK	Parwatarikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354 1993											
	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of $\kappa$ Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508											
	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490											
	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823											
	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34											
g/s	IP	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149 1997											
	IQ	Wikler, et al., "N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20											
EXAMINER								DATE CONSIDERED					
g/s								7/20/07					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866							
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.									
				FILING DATE: October 21, 2003		GROUP: 1615							
<b>U.S. PATENT DOCUMENTS</b>													
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	JA	5	5	5	5	2	5	0	12/15/1998	Miller, et al.	264	460	
	JB	5	5	5	5	2	5	1	02/09/1999	Wong, et al.	424	473	
	JL	5	5	7	5	5	0	9	03/09/1999	Heafield, et al.	424	464	
	JD	5	5	5	1	4	7	2	04/06/1999	Miller, et al.	424	468	
	JL	5	5	0	5	5	5	9	06/01/1999	Miller, et al.	424	282	
	JL	5	5	5	5	5	5	2	09/28/1999	Oshlack, et al.	424	468	
	JG	5	5	5	5	5	5	9	09/28/1999	Chasin, et al.	424	460	
	JH	5	5	6	5	1	6	1	10/12/1999	Oshlack, et al.	424	457	
	JL	5	9	5	5	1	5	1	10/12/1999	Miller, et al.	424	468	
	JJ	5	5	5	5	5	5	1	10/19/1999	Oshlack, et al.	424	468	
<b>FOREIGN PATENT DOCUMENTS</b>													
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
										YES	NO		
	JK												
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
	JJ	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110											
	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58											
	JL	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
	JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529											
	JQ	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258											
	JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526											
	JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1995) Vol 60, No. 2, pg. 206-217											
	EXAMINER						DATE CONSIDERED						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866								
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1613								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
J/S	KA	6	0	7	6	6	6	2	02/15/2000	Oshlack, et al.	424	476		
	KE	6	0	6	6	6	6	5	05/30/2000	Leslie, et al.	424	469		
	KF	6	0	1	7	8	3	3	06/20/2000	Malikowska, et al.	424	457		
	KO	6	0	7	7	8	3	3	06/20/2000	Oshlack, et al.	424	457		
	KE	6	1	0	3	2	6	3	08/15/2000	Simon	424	449		
	KF	8	1	0	8	8	8	8	08/15/2001	Chasin, et al.	424	449		
	KG	8	8	4	3	3	1	2	11/07/2000	Sackler, et al.	424	449		
	KH	8	1	8	8	3	1	8	11/07/2000	Heafield, et al.	424	457		
	KF	8	1	8	8	1	8	7	12/19/2000	Miller, et al.	424	457		
	KA	8	8	8	0	8	1	3	07/03/2001	Oshlack, et al.	424	476		
J/S	KK	8	8	5	1	8	8	2	07/03/2001	Miller, et al.	424	457		
	KL	8	7	8	8	5	8	6	07/17/2001	Oshlack, et al.	424	457		
	KF	8	1	8	8	8	8	8	09/25/2001	Oshlack, et al.	424	457		
	FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
J/S	KF	0	8	8	7	7	8	5	05/31/2001	WO (A2)	A61K			
	KO	0	1	8	7	8	8	3	07/26/2001	WO (A1)	A61K	31/485		
	KP	0	1	8	5	8	5	7	11/15/2001	WO (A2)	A61K			
J/S	KQ	0	8	8	3	8	8	8	12/13/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
J/S	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans", Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82												
J/S	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets", Arzneim.-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022												
EXAMINER  James Y. Smith									DATE CONSIDERED 7/23/07					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,866	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: October 21, 2003	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	LA	6 6 6 6 6 3 5	10/23/2001	Oshlack, et al.	424	400	
	LB	6 3 6 6 6 6 7	12/04/2001	Miller, et al.	424	400	
	LG	6 3 6 6 6 6 3	01/01/2002	Oshlack, et al.	424	400	
	LD	5 3 7 5 6 6 7	04/23/2002	Kaiko, et al.	424	400	
	LF	6 3 6 7 6 6 5	05/14/2002	Oshlack, et al.	424	400	
JS	LG	5 5 5 5 5 5 5	06/04/2002	Miller, et al.	424	400	
	LN	5 6 7 5 6 6 5	11/05/2002	Kaiko, et al.	424	400	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	LH						
	LI						
	LJ						
	LK						
	LL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	LM						
	LI						
	LD						
	LN						
EXAMINER  <i>James J. Smith</i>				DATE CONSIDERED  <i>1/25/07</i>			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/689,866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Ostlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

'EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	MA	5 9 5 0 7 0 4	12/99	Milch et al.	514	210.16	
	ME	5 9 7 7 0 0 4	10/99	Foss	514	282	
	MC	5 9 0 0 0 0 7	10/99	Reder et al.	424	449	
	MD	5 9 1 2 0 1 1	8/99	Chasin et al.	424	426	
	ME	5 9 0 0 0 3 0	3/99	Hill	514	282	
	ME	5 5 5 1 5 4	2/95	Kuczynski et al.	424	472	
	MG	5 5 5 5 5 0	1/99	Demopoulos et al.	604	49	
	MR	5 9 0 0 0 4 4	1/99	Demopoulos et al.	604	890.1	
	ME	5 9 5 0 1 0 0	6/99	Crain et al.	514	282	
	MJ	5 6 3 3 2 5 5	5/97	Qin et al.	514	282	
	MR	5 6 2 4 3 3 2	4/97	Qin et al.	514	282	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
JS	ML	19 8 5 5 5 5 5	6/98	DE	A81K	31/485		
	MM	29 7 0 0 0 5 0	2/97	DE	A81K	31/485		
	MR	4 9 2 5 5 5 5	2/95	DE	A81K	31/485	X	
	MC	2 9 2 2 5 3 5	11/72	DE	A81K	27/00		
JS	MR	5 0 5 3 1 5 2	6/99	EP	A81K	31/485		

## OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)

JS	MR	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.
	MR	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.
JS	MS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
101669,896

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1515




## U.S. PATENT DOCUMENTS

US PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	NA	8	5	4	8	8	0	2	4/97	Khanna et al.	514	399	
	NB	5	8	2	8	4	4	8	12/96	Crain et al.	514	12	
	NF	8	5	8	0	2	8	2	12/96	Crain et al.	514	282	
	NC	5	5	7	3	2	2	2	11/96	Portoghese et al.	546	35	
	NF	8	8	4	4	0	8	2	11/96	Rose et al.	514	343	
	NF	5	5	5	5	8	8	8	9/96	Mayer et al.	514	282	
	NG	5	5	4	5	8	2	2	7/96	Aston et al.	514	608	
	NH	5	8	4	2	8	8	0	5/96	Weber et al.	514	249	
	NK	5	5	4	2	8	7	8	4/96	Crain et al.	514	282	
		NJ	5	8	0	4	0	8	9	3/96	Mayer et al.	514	289
NK		8	4	8	8	3	6	2	1/96	Kitchell et al.	424	426	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
J/S	NF	0 8 4 2 4 4 8	4/96	EP	A61K	31/485		
	NM	0 2 8 2 3 8 4	4/90	EP	A61K	31/485		
	NN	0 2 6 8 2 8 8	12/86	EP	A61K	9/22		
J/S	NO	8 3 3 2 4 8 0	1/96	WO	A61K	31/485		
	NF	8 8 4 8 8 8 8	4/96	WO	A61K	31/485		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	NQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.
	NR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.
EXAMINER		
		DATE CONSIDERED 7/23/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10689.866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	OA	0 4 2 2 0 4 4	12/95	Crain et al.	514	12	
	OK	0 1 5 2 2 2 2	10/95	Portoghese et al.	546	35	
	OC	0 4 2 0 1 1 2	6/95	Zagon et al.	514	282	
	OD	0 1 2 0 0 0 2	12/94	Ockert	514	282	
	OE	5 3 5 5 2 2 2	10/94	Bihari et al.	514	282	
	OE	5 3 5 2 2 2 3	10/94	Mayer et al.	514	289	
	OG	5 3 5 2 2 2 2	10/94	Portoghese et al.	514	289	
	OK	0 2 2 2 0 1 2	5/94	Mayer et al.	514	25	
	OK	5 2 1 2 2 2 2	5/94	Borsodi et al.	514	282	
	OJ	0 3 1 0 2 2 2	5/94	Rose et al.	424	35	
JS	OK	0 2 2 3 2 2 2	12/93	Oshlack et al.	424	282	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
JS	OL	0 2 3 2 0 2 0	9/97	WO	A61K	9/20		
	OM	0 0 0 2 2 2 1	2/96	WO	A61K	31/485		
	OA	0 0 0 1 0 0 1	2/96	WO	A61K	31/485		
	OO	0 1 0 0 4 2 0	3/94	WO	A61K	31/46		
JS	OK	0 2 0 3 2 2 1	9/93	WO	A61K	9/22		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JS	OQ	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.					
JS	OR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocaine, Hydrobromophene and their Combination in Humans," (1996).					
EXAMINER	Sumera Y. Patel			DATE CONSIDERED	7/23/07		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/669,866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
9/8	PA	0 2 0 6 6 6 0	10/93	Askanazi et al.	514	262	
	PP	0 2 3 0 2 0 0	8/93	Lee et al.	424	449	
	PE	0 2 2 0 4 4 0	7/93	London et al.	514	535	
	PP	0 4 4 0 6 4 0	9/92	Granger et al.	424	449	
	PE	0 4 0 2 6 0 4	4/92	Goldberg	514	282	
	PE	0 0 0 6 7 4 5	3/92	Sindair	424	449	
	PG	0 0 0 6 0 0 8	2/92	Sindair et al.	514	282	
	PP	0 0 2 0 4 0 4	12/91	Mendelson et al.	514	282	
	PI	4 0 3 0 4 2 0	6/90	Lewis	514	282	
	PJ	0 0 0 0 0 0 0	12/89	Rzesutowski et al.	514	282	
9/8	PP	0 0 0 2 3 3 5	11/89	Sindair	514	282	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	PL						

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


9/8	PM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.
	PN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.
	PO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.
	PP	Physician's Desk Reference 48 <sup>th</sup> Ed. (1994) Montvale, NJ, 2120-2121.
9/8	PO	Foss et al., J. Clin Pharmacol (1993), 33:747-751.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,856								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: October 21, 2003		GROUP: 1615								
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
9/8	QA	5	6	7	3	6	7	6	10/89	Fishman et al.	412	10		
	QB	1	8	8	1	1	8	1	8/89	Goldberg	514	282		
	QE	5	8	5	5	5	8	8	8/89	Oshlack et al.				
	QD	5	8	5	6	5	5	8	2/89	Wuest et al.	514	381		
	QE	7	8	0	8	6	4	8	2/89	Choi	514	18		
	QF	4	6	0	0	0	7	4	2/89	Chien et al.	424	282		
	QG	7	6	5	3	8	0	8	2/89	Pasternak	514	282		
	QH	4	7	6	5	0	0	0	11/88	Kreek et al.	514	282		
	QH	7	7	6	6	0	7	2	9/88	Kreek et al.	514	282		
	9/8	QJ	7	7	6	0	0	0	9	7/88	Rziszotanski et al.	514	282	
QH		7	7	3	0	0	4	6	3/88	Portoghese et al.	545	10		
<b>FOREIGN PATENT DOCUMENTS</b>														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
		QH												
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
9/8	QM	Holmes et al., Anesth. Analg. (1993), 77:1166-73.												
	QH	Mlaskowski et al., Brain Research (1992), 596:41-45.												
	QO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone In Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.												
	QF	Cappel et al., Pharma. Bioch. & Behav. (1989), 34:425-427.												
9/8	QO	Vaccarino et al., Pain (1989), 36:103-109.												
	QO	Gonzalez et al., "Naltrexone: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.												
EXAMINER 									DATE CONSIDERED 07/23/07					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON		SERIAL NO.: 10/689,666	
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT(S): Ostlack, et al. FILING DATE: October 21, 2003 GROUP: 1615			
(Use several sheets if necessary)							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JS	RA	4 1 1 0 1 1 0	4/87	Goldberg	514	260	
	RB	4 6 0 4 4 6 7	4/87	Lewis et al.	514	282	
	RC	4 6 6 6 6 7 6	8/86	Pasternak	514	282	
	RD	4 6 0 1 6 6 0	8/86	Lewis et al.	514	260	
	RE	4 6 7 3 6 6 6	3/86	Chen et al.	604	896	
	RF	4 4 0 4 3 7 6	8/84	Hussain et al.	424	260	
	RG	4 4 0 1 0 0 3	7/84	Gordon et al.	424	260	
	RF	4 4 0 1 4 7 0	5/84	Ganti	424	260	
	RF	4 1 0 4 0 7 1	8/83	Portoghesi et al.	424	260	
	RJ	4 1 7 0 1 6 0	11/79	Goldberg	424	260	
JS	RK	3 0 0 0 0 4 0	6/76	Pachter et al.	424	260	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	RG						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
JS	RM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.					
	RN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.					
	RO						
	RI						
	RI						
EXAMINER <i>James J. Dwyer</i> DATE CONSIDERED <i>7/23/07</i>							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
101669,866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JS</i>	SK	9 8 1 9 0 0 5	4/75	Pachter et al.	424	260	
	SB	3 7 7 3 0 0 5	11/73	Pachter et al.	424	260	
	SC	3 0 7 0 5 0 7	7/72	Lachman et al.	424	260	
	SH	9 1 9 9 9 9 7	2/70	Lowenstein et al.	424	260	
	SC	9 9 9 1 9 5 0	7/67	Blumberg et al.	260	260	
	SC	7 7 7 0 9 9 0	11/56	Fromherz et al.	167	65	
	SC	0 0 0 1 0 7 0	12/99	O'Malley et al.	514	282	
	SH	0 3 7 0 9 0 0	9/00	Whitling	424	497	
	SI	9 5 1 9 5 3 9	06/03	Hirsch et al.	424	484	
	SJ	0 0 0 9 0 1 5	08/03	Foss et al.	514	260	
<i>JS</i>	SK	5 1 1 5 1 1 9	04/04	Oshlack et al.	514	200	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
SL							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JS</i>	SM	Bentley, Function of Myocardial $\alpha$ -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112
	SN	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577
	SO	Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240
	SP	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a $\mu$ , $\delta$ or $\kappa$ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288
	SQ	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38
	SR	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79
<i>JS</i>	SS	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/688,866

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Oshlack, et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
9/8	TA	6	2	2	8	8	8	3	05/08/01	Palermo et al.	514	282	
	TB	6	2	2	8	8	8	7	08/21/01	Kaiko et al.	424	400	
	TE	6	6	2	7	8	3	5	09/03	Palermo et al.	514	282	
	TD	6	6	9	5	5	5	6	02/04	Kaiko et al.	424	400	
	TE	6	4	7	8	8	8	4	11/02	Kaiko et al.	424	400	
9/8	TF	7	1	4	8	5	8	7	12/06	Oshlack et al.	424	490	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
9/8	TG	WO	98	2	8	8	8	3	06/18/98	EPO	A61K	31/485		X
	TH	WO	00	3	8	8	8	9	07/06/00	EPO	A61K	9/00		X

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

9/8	TI	Life Sci. 1982 31 pg 101-104											
	TJ	J Pharm. Exper. Ther. 1991 259(2) pg 582-589											
	TR	Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539											
	TE	J. Clin. Invest. 1988 82(5) pg 1574-1577											
	TM	Brain Res. 2001 888 pg 75-82											
	TN	Res. Comm. Sust. Abuse 1991 12(3) pg 119-131											
	TC	Brain Res. Bull. 1994 33(2) pg 237-240											
	TR	FEBS Lett. 1994 347, pg 284-288											
	TO	FEBS Lett. 1994 341 pg 33-38											
	TR	FEBS Lett. 1994 346 pg 75-79											
	TS	Neuroscience 1998 82, pg 223-240											
	TT	J. Neuro Sci 1998 18, pg 9685-9694											
	TU	Neurosci. Lett. 1999 272, pg 183-186											
9/8	TV	Eur. J. Pharmacol. 2000 404, pg 153-159											

EXAMINER

DATE CONSIDERED

7/23/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-148  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1133CONSERIAL NO.:  
10/689,866

ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)  
Benjamin OSHLACK et al.FILING DATE:  
October 21, 2003GROUP:  
1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/HS/	AJ	Philip D. Kanof et al., "Levels of Opioid Physical Dependence in Heroin Addicts," Drug and Alcohol Dependence, 27 (1991) 253-262.
/HS/	AK	J.E. Peachey et al., "Assessment of Opioid Dependence with Naloxone," British Journal of Addiction (1988) 83(2), 193-201
/HS/	AL	John G. Nutt et al., "Methadone-naloxone Mixtures for Use in Methadone Maintenance Programs," Clinical Pharmacology and Therapeutics, Vol. 15, Number 2, pp. 158-166, received for publication June 11, 1973
/HS/	AM	Richard I. H. Wang et al., "Rating the Presence and Severity of Opiate Dependence," Clinical Pharmacology and Therapeutics, Volume 16, Number 4, pp. 653-657; received for publication January 21, 1974
/HS/	AN	Richard B. Resnick et al., "Naloxone Precipitated Withdrawal: A Method For Rapid Induction Onto Naltrexone," Clinical Pharmacology and Therapeutics, Volume 21, Number 4, pp. 409-413; received for publication November 16, 1976
/HS/	AO	Barbara A. Judson et al., "The Naloxone Test Opiate Dependence," Clin. Pharmacol. Ther., Vol. 27, Number 4, pp. 492-501, received for publication September 15, 1979
/HS/	AP	Philip D. Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects," The Journal of Pharmacology and Experimental Therapeutics, Vol. 260, No. 1, pp. 355-363, 1992
/HS/	AQ	Richard L. Wiesen et al., "The Safety and Value of Naloxone as a Therapeutic Aid," Drug and Alcohol Dependence, 2 (1977) pp. 123-130
	AR	
	AS	

EXAMINER

/Humera Sheikh/

DATE CONSIDERED

07/23/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.